Moving beyond "how much" to "is it working." This learning path introduces the paradigm shift from expression-based to function-based molecular measurement.
For decades, clinical biomarkers have answered one question: how much protein is present? Immunohistochemistry (IHC) stains tissue sections, pathologists score intensity, and patients are stratified accordingly. But this approach has a fundamental blind spot.
A protein can be highly expressed but inactive. It can be present in abundance yet never engage its binding partner. It can sit on a cell surface doing nothing while patients receive therapies that assume it's working. The result? Patients who should respond don't. Patients who shouldn't respond do. For those living with cancer—and for their families—this uncertainty compounds an already overwhelming situation.
Functional biomarkers solve this by measuring what proteins are actually doing: Are they binding their partners? Are they phosphorylated? Are they in the right conformation to signal? This learning path will show you why this distinction matters and how FLIM-FRET technology makes it measurable.
Before diving into specific techniques, we need to understand the fundamental distinction that underlies everything else. Why does measuring protein function give different answers than measuring protein amount? The answer lies in the difference between presence and activity.
Now that you understand why function matters, let's look at how proteins actually work. Biology happens through molecular interactions: receptors bind ligands, enzymes engage substrates, checkpoint receptors clasp their partners. These protein-protein interactions are the fundamental unit of biological function, and detecting them is the key to functional measurement.
Here's where it gets tricky. With conventional microscopy, you might see two proteins in the same region of a cell and assume they're interacting. But "nearby" is not the same as "touching." Standard fluorescence microscopy has a resolution limit of about 200-300 nanometers; protein interactions happen at 1-10 nanometers. That's a 20-fold gap between what you can see and what you need to measure.
The research community recognized this problem and developed clever workarounds. Proximity Ligation Assay (PLA) uses DNA circularization and rolling-circle amplification to detect proteins within ~30-40nm of each other. It's closer to interaction distance, and it's been widely adopted. But there's a catch: 30nm is still 3-4x larger than actual interaction distance. PLA tells you proteins are in the same corridor; it can't confirm they're in the same room having a conversation.
So far we've focused on whether proteins are bound to each other. But there's another dimension of function: whether a protein is switched on. Kinases become active when phosphorylated. Receptors change conformation when ligand-bound. These activation states represent another layer of functional information that expression completely misses. Measuring them requires detecting the subtle conformational and modification changes that distinguish active from inactive proteins.
You now understand why functional biomarkers matter: expression doesn't predict function, conventional methods can't reach interaction distance, and activation states add another layer of complexity. For patients awaiting treatment decisions, better biomarkers could mean less uncertainty. The next step is learning how FLIM-FRET technology addresses these challenges.
Continue to Core Technology
